Hemab Therapeutics Holdings, Inc. (COAG)
About Hemab Therapeutics Holdings, Inc.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$22.7M
- Total assets
- $175.3M
- Market cap
- $1.2B
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.2B
- Shares outstanding
- 25.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 1, 2026
Hemab Therapeutics Holdings, Inc. (COAG) Stock Price
- Reported a net loss of $22.7M.
- Trading 4% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Hemab Therapeutics Holdings, Inc..
Write a review
News about Hemab Therapeutics Holdings, Inc.
News & sentiment via Polygon.io
Hemab Therapeutics Holdings, Inc.: frequently asked questions
Is Hemab Therapeutics Holdings, Inc. an American company?
Hemab Therapeutics Holdings, Inc. is a US-based company headquartered in Cambridge, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Hemab Therapeutics Holdings, Inc. headquartered?
Hemab Therapeutics Holdings, Inc. is headquartered in Cambridge, Massachusetts, United States.
Is Hemab Therapeutics Holdings, Inc. publicly traded?
Yes — Hemab Therapeutics Holdings, Inc. is a publicly traded company. Its stock trades under the ticker symbol COAG on the NASDAQ.
What does Hemab Therapeutics Holdings, Inc. do?
Hemab Therapeutics Holdings, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
